Scrambler Therapy for chemotherapy-related nerve pain (CIPN).

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with persistent CIPN receive up to ten daily one-hour sessions of Scrambler Therapy delivered through adhesive electrodes placed near areas of pain, tingling, or numbness. Some participants may be assigned to active Scrambler Therapy while others receive a sham or no-intervention control to compare effects. The study measures changes in neuropathic pain intensity, related symptoms, function, and quality of life. Treatment may stop early if participants no longer report neuropathic pain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults with CIPN-related pain for at least three months duration, and for which the participant wants intervention
* At least three months from the last dose of neurotoxic cancer-directed drug
* No plan (at the time of study enrollment) for additional neurotoxic cancer-directed therapies for at least five months after trial enrollment
* Pain rated ≥ four out of 10 in severity (0-10 pain scale) during the seven days prior to enrollment
* \> Six-month life expectancy
* Able to complete questionnaires by themselves or with assistance
* Able to provide informed written consent
* ECOG Performance Status score ≥ two
* Not currently enrolled in another research study for pain or neuropathy

Exclusion Criteria:

* Pregnant or nursing
* An operational implanted drug delivery system, implanted electronic medical device, life supporting medical device, and/or medical monitoring device
* History of myocardial infarction or ischemic heart disease within six months of trial enrollment
* History of epilepsy, brain damage resulting in seizure activity, or use of anticonvulsants for seizure
* Skin conditions such as open sores that will prevent proper application of electrodes
* Unwillingness or inability to wean and discontinue gabapentin or pregabalin prior to the start of ST
* History of symptomatic peripheral neuropathy prior to receiving neurotoxic chemotherapy
* Prior treatment with Scrambler Therapy
* The presence of chronic regional pain syndrome (CRPS) in the scrambler therapy treatment area.

Where it's running

• Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Laura Shoemaker, DO, MS, FAAHPM — Case Comprehensive Cancer Center, Cleveland Clinic
• Study coordinator: Laura Shoemaker, DO, MS, FAAHPM
• Email: shoemal@ccf.org
• Phone: (216) 444-5193

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cryotherapy during weekly paclitaxel to reduce chemotherapy-induced numbness and tingling

  This study tests whether applying cryotherapy to hands and feet during weekly paclitaxel helps prevent CIPN in women with breast cancer.

  Recruiting at 3 sites Azienda Sanitaria dell'Alto Adige · Bolzano, Bolzano and 3 other locations · NCT07780955

• VMD-3866 topical gel for chemotherapy-induced nerve pain

  This trial will test whether a non-opioid topical gel called VMD-3866 can reduce pain in adults with chemotherapy-induced peripheral neuropathy.

  Recruiting Phase 2 VM Therapeutics LLC · London, UK · NCT07072468

• Cryocompression to prevent taxane-induced nerve damage in the arms and legs.

  This study tests whether cooling and pressure applied to the arms and legs during taxane chemotherapy can prevent or reduce numbness, pain, or weakness from peripheral neuropathy in adults with breast or gynecologic cancer.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07064798

• Explicit Sensory Retraining for Chemo-Induced Peripheral Neuropathy

  This study tests whether three sessions of explicit sensory retraining for the legs, compared with usual care, can help reduce symptoms and improve function in adults with CIPN after chemotherapy.

  Recruiting Assaf-Harofeh Medical Center · Tzrifin · NCT06724861

• SIR2501 plus Paclitaxel for solid tumors

  This Phase 2 study tests SIR2501 in adults with solid tumors who are starting paclitaxel chemotherapy to see if it is safe and tolerable and to explore its effect on chemotherapy-induced neuropathy.

  Recruiting at 3 sites Phase 2 Sironax USA, Inc. · Hollywood, Florida and 4 other locations · NCT07765446

• Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors

  This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07673614

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.